Agenus Inc AGEN:NASDAQ

Last Price$2.60Cboe Real-Time Last Sale as of 12:29PM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.05(1.76%)
Bid (Size)$2.59 (1,303)
Ask (Size)$2.60 (2,000)
Day Low / High$2.57 - 2.65
Volume940.1 K
 

View Biotechnology IndustryPeer Comparison as of 01/31/2023

 

Agenus Inc ( NASDAQ )

Price: $2.60
Change: +0.05 (1.76%)
Volume: 940.1 K
12:29PM ET 1/31/2023
 
 

Alector Inc ( NASDAQ )

Price: $8.80
Change: +0.16 (1.85%)
Volume: 79.7 K
12:28PM ET 1/31/2023
 
 

Cymabay Therapeutics Inc ( NASDAQ )

Price: $8.26
Change: -0.05 (0.60%)
Volume: 590.8 K
12:26PM ET 1/31/2023
 
 

ANI Pharmaceuticals Inc ( NASDAQ )

Price: $44.46
Change: +1.71 (4.00%)
Volume: 22.3 K
12:23PM ET 1/31/2023
 
 

AnaptysBio Inc ( NASDAQ )

Price: $24.52
Change: +0.58 (2.42%)
Volume: 175.9 K
12:29PM ET 1/31/2023
 

Read more news Recent News

Agenus Says Trial Results Showed 'Durable Responses' of Botensilimab, Balstilimab Combination in Colorectal Cancer
3:31PM ET 1/23/2023 MT Newswires

Agenus (AGEN) said Monday that data from a 70-patient group in a Phase 1b study of botensilimab combined with balstilimab to treat colorectal cancer showed...

Agenus Registers for Potential Secondary Offering of Up to 2 Million Common Shares
3:33AM ET 12/27/2022 MT Newswires

Agenus (AGEN) late Friday registered with the US Securities and Exchange Commission for the potential resale of up to about 2 million common shares by some...

--EF Hutton Starts Agenus With Buy Rating, Sets Price Target at $8.30
7:40AM ET 12/22/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--EF Hutton Initiates Agenus With Buy Rating, Price Target is $8.3
7:59AM ET 12/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Agenus' Updated Data Confirms Long-Term Potential Value
9:51AM ET 1/24/2023 Seeking Alpha

Agenus: Advancement Of Botensilimab Could Create A Great Pivot Point
5:57AM ET 12/13/2022 Seeking Alpha

Agenus: Perpetually Getting There
12:17PM ET 12/12/2022 Seeking Alpha

MiNK Therapeutics Undervalued Given Potential Of Platform
10:43PM ET 12/05/2022 Seeking Alpha

Company Profile

Business DescriptionAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA. View company web site for more details
Address3 Forbes Road
Lexington, Massachusetts 02421-7305
Phone+1.781.674.4400
Number of Employees294
Recent SEC Filing01/09/20234
Chairman & Chief Executive OfficerGaro H. Armen
Chief Financial & Accounting Officer, VP-FinanceChristine M. Klaskin
Chief Medical OfficerSteven O’Day
Chief Information OfficerCraig Winter

Company Highlights

Price Open$2.58
Previous Close$2.55
52 Week Range$1.25 - 3.37
Market Capitalization$791.0 M
Shares Outstanding304.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.81
Beta vs. S&P 500N/A
Revenue$36.8 M
Net Profit Margin-238.59%
Return on Equity-2,585.10%

Analyst Ratings as of 12/07/2022

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset